Jennifer Wu, MD, assistant professor of medicine, NYU School of Medicine, discusses the issue of deficiencies in enzymes that fix mismatch repairs in colorectal cancer. Wu says targeting the cancer-specific enzymes which allow tumors to repair themselves could stop tumor growth in patients.
John Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, discusses the individualization of treatment of patients with colorectal cancer (CRC).
A first-in-human phase I dose-escalation study followed by a small expansion cohort, both of which were conducted solely in Germany, set the stage for what would soon become the FDA-approved dose for regorafenib (Stivarga) of 160 mg/day.
As with each new line of therapy, regorafenib offers a unique challenge in terms of AE management. AEs associated with regorafenib have been reported across several clinical trials, including the pivotal CORRECT trial, the Asian CONCUR study, and the phase IIIb CONSIGN trial. More recently, a clinical case study demonstrated the utility of regorafenib in a
A new treatment delivery method is being explored that combines real-time imaging with convection-enhanced delivery of chemotherapy for patients with high-grade gliomas, according to the lead investigator of early phase research exploring the approach, Nicholas A. Butowski, MD.
Preclinical research conducted on tumor samples and mouse models showed that FGL2 is secreted by glioblastoma, which causes the upregulation of immune suppression mechanisms. Additionally, in these early studies, an anti
To gain further insight into TAS-102 and regorafenib, Targeted Oncology spoke with Tanios Bekaii-Saab, MD, on how he utilizes currently available data to provide optimal care for patients with chemorefractory CRC.